In the liver, empagliflozin protects from lipotoxicity and NAFLD through several mechanisms: reducing lipogenesis, modifying the expression of cytochrome proteins, increasing Nrf2, decreasing fetuin-A and reducing circulating pro-inflammatory cytokines (95). Here, AHSG is linked to metabolic dysfunction-associated steatotic liver disease.